Antipodes Partners LTD Immunome Inc. Transaction History
Antipodes Partners LTD
- $3 Billion
- Q2 2025
A detailed history of Antipodes Partners LTD transactions in Immunome Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 10,261 shares of IMNM stock, worth $127,031. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,261
Previous 14,164
27.56%
Holding current value
$127,031
Previous $95,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding IMNM
# of Institutions
148Shares Held
66.5MCall Options Held
44.9KPut Options Held
4.24M-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.28MShares$102 Million0.05% of portfolio
-
Redmile Group, LLC San Francisco, CA4.87MShares$60.3 Million5.51% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.69MShares$58 Million0.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$56 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.08MShares$50.5 Million3.27% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $150M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...